The Effectiveness of 0.5% Atropine in Controlling High Myopia in Children
Overview
Pharmacology
Affiliations
Twenty highly myopic children (> or = -6.0 D) were treated with 0.5% atropine eyedrops once per night. Twelve subjects were initially treated with a short-acting cycloplegic agent, tropicamide (0.5%) (Group A), and the other eight subjects did not receive any myopic therapy before atropine (Group B). These cases were followed for up to five years. In Group A, the mean myopic progression rate after 0.5% atropine treatment was -0.01 +/- 0.04 D/M (Diopter/Month), which was significantly lower than that of the period during tropicamide treatment (-0.12 +/- 0.09 D/M) (p < 0.05). In Group B, the mean myopic progression rate after atropine therapy was begun was -0.04 +/- 0.06 D/M, which was also significantly slower than that of non-medication, -0.14 +/- 0.07 D/M (p < 0.05). The results suggested that 0.5% atropine is effective for slowing down myopic progression, even in highly myopic children.
High myopia control is comparable between multifocal rigid gas-permeable lenses and spectacles.
Yu L, Zhuo R, Song G, Lin M, Jin W Front Med (Lausanne). 2023; 10:1207328.
PMID: 37636562 PMC: 10449577. DOI: 10.3389/fmed.2023.1207328.
Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial.
Repka M, Weise K, Chandler D, Wu R, Melia B, Manny R JAMA Ophthalmol. 2023; 141(8):756-765.
PMID: 37440213 PMC: 10346510. DOI: 10.1001/jamaophthalmol.2023.2855.
Parasympathetic and sympathetic control of emmetropization in chick.
Rucker F, Taylor C, Kaser-Eichberger A, Schroedl F Exp Eye Res. 2023; 232:109508.
PMID: 37230289 PMC: 10452042. DOI: 10.1016/j.exer.2023.109508.
Interventions for myopia control in children: a living systematic review and network meta-analysis.
Lawrenson J, Shah R, Huntjens B, Downie L, Virgili G, Dhakal R Cochrane Database Syst Rev. 2023; 2:CD014758.
PMID: 36809645 PMC: 9933422. DOI: 10.1002/14651858.CD014758.pub2.
Myopia, its prevalence, current therapeutic strategy and recent developments: A Review.
Singh H, Singh H, Latief U, Tung G, Shahtaghi N, Sahajpal N Indian J Ophthalmol. 2022; 70(8):2788-2799.
PMID: 35918918 PMC: 9672758. DOI: 10.4103/ijo.IJO_2415_21.